Loading
companiesCompany
SOFIE Biosciences
SOFIE Biosciences is a US radiopharmacy network running two phase 3 trials of the FAP PET tracer [18F]FAPI-74 in pancreatic and gastro-oesophageal cancer.
Overview
SOFIE Biosciences, based in Dulles, Virginia, is a US radiopharmacy network running two phase 3 trials of the FAP PET tracer 18F-FAPI-74 in pancreatic and gastro-oesophageal cancer. First patients were dosed in the FAPI-GO gastro-oesophageal trial in December 2025 and the pancreatic trial in February 2026, seven radiopharmacies have been cleared to manufacture 18F-FAPI-74 with twelve-hour shelf-life distribution planned in 2026, and the FAPI chemistry originated at Heidelberg. OnCo links it to pancreatic, gastric and oesophageal cancer, to FAPI PET and PET, to FAP as a target, to Heidelberg University Hospital and the DKFZ, and to PET tracer manufacturing and radiopharmacy networks. Whether FAP imaging changes staging and treatment in cancers where FDG PET falls short is the question the phase 3 trials will answer. The FAPI PET technology page carries the evidence.
Headquarters
Dulles, VA, US
Scorecard
All companies#156of 1244 companies, score 39
- approved products +6
- modalities +2
- regions +1
- registry trials +30
1 approved, 0 in phase 3, 0 earlier, 0 targets, 242 registry studies. Formula on the scorecards page.
Website
ApprovedPET imaging agent (glucose analogue)
Fludeoxyglucose F-18 (FDG) · FDG (multiple manufacturers)
The radioactive sugar used in almost every cancer PET scan, approved in the 1990s and made fresh each day by regional cyclotrons.
Similar pages
- CompanyPETNET Solutions (Siemens Healthineers)
Shares Fludeoxyglucose F-18 (FDG), PET tracer manufacturing and distribution, Radiopharmacy and cyclotron networks, Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211).
- CompanyCardinal Health Nuclear & Precision Health Solutions
Shares Fludeoxyglucose F-18 (FDG), PET tracer manufacturing and distribution, Radiopharmacy and cyclotron networks, Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211).
- CompanyJubilant Radiopharma
Shares PET tracer manufacturing and distribution, Radiopharmacy and cyclotron networks, Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211).
- PersonFrederik Giesel
Shares Heidelberg University Hospital / NCT / DKFZ, FAPI PET, FAP.
- IdeaFAPI PET as the workup for MCED positives
Shares FAPI PET, FAP, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma.
- TechnologyMedical cyclotrons, hot cells, and synthesis modules
Shares PET tracer manufacturing and distribution, Radiopharmacy and cyclotron networks, Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211), PET (positron emission tomography).
- TechnologyCAR-T against stroma: fibroblasts and myeloid cells
Shares FAPI PET, FAP, Pancreatic ductal adenocarcinoma.
- PersonUwe Haberkorn
Shares Heidelberg University Hospital / NCT / DKFZ, FAPI PET, FAP.
cancers
fronts
technologies
targets
drugs
ApprovedPET imaging agent (glucose analogue)
Fludeoxyglucose F-18 (FDG) · FDG (multiple manufacturers)